Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
Although BCR-ABL tyrosine-kinase inhibitor (imatinib) is effective front-line therapy for chronic myeloid leukemia (CML), drug resistance is a well-recognized problem. In the present study, we found that the stimulation of TLR4 signaling pathway up-regulates BCR-ABL protein levels and may contribute to imatinib resistance. Heat shock proteins appear to be involved in the protein stability of BCR-ABL. Our findings provide new insight into the role of the TLR4 signaling pathway in drug resistance, and may have implications for the development of new therapeutic strategies to overcome drug resistance in CML.
|